Abstract
The study investigated whether the introduction of atypical neuroleptics in the formulary of a large community mental health clinic had any impact on demand for services, quality of life, symptom presentation and cost of care of patients with chronic psychotic illnesses over a 3-year period. BJC Behavioral Health Services provides and coordinates mental health services for citizens residing in St. Louis City, St. Louis County and the counties of St. Francois, Iron and Washington, MO. We searched the BJC Behavioral Health Services and the Missouri Pharmacy Database to identify patients who had been switched from a typical to an atypical neuroleptic for a minimum of 3 months between 5/1/1997 and 4/30/2000. We excluded patients treated with more than one neuroleptic simultaneously and those with incomplete records. The primary outcome measures were: level of care assignment. Secondary outcomes were a quality of life scale, and a symptom severity inventory. Twenty-five patients met final entry criteria (out of a census of 6280 patients on 3/6/2000). In this naturalistic sample of patients with chronic severe psychotic symptoms, atypical neuroleptic treatment resulted in a marked reduction in demand of services, marked improvement o...Continue Reading
References
May 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·M FranzB Gallhofer
Apr 6, 1999·Schizophrenia Research·D A Revicki
Jun 9, 1999·Comprehensive Psychiatry·M SajatovicR McCormick
Jul 9, 1999·Clinical Therapeutics·A K MallaS Zirul
Nov 23, 2000·Acta Psychiatrica Scandinavica·R M NormanA Rickwood
Dec 1, 2000·BMJ : British Medical Journal·J GeddesP Bebbington
Jan 15, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael RitsnerIlan Modai
Sep 12, 2002·Schizophrenia Research·L VorugantiA Awad
Mar 29, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Patricia ThiedaJohn Kane
Citations
Feb 20, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Simon FreyTom Stargardt
Apr 21, 2012·L'Encéphale·L ZouariM Maâlej
Nov 26, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hee Yeon JungYong Sik Kim
Feb 17, 2007·Schizophrenia Research·Peter M WehmeierWolfgang Schreiber
Feb 10, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Peter M WehmeierWolfgang Schreiber
Jan 17, 2008·Journal of Intellectual Disability Research : JIDR·S L RuedrichK Lim
Aug 28, 2007·Journal of Psychiatric Research·Peter M WehmeierMartin Lambert
Jul 18, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michael S Ritsner, Anatoly Gibel
Oct 25, 2016·Neuroscience·Christine GottschlingAndreas Faissner
Sep 30, 2009·Clinical Rehabilitation·Zhen-hua ChenHong-bing Mei
Aug 18, 2006·Human Psychopharmacology·Moon-Soo LeeIn-Kwa Jung
Nov 4, 2005·Clinical Rheumatology·Hatice BodurGülcan Kural
Dec 20, 2007·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
Mar 25, 2011·Psychopharmacology·Tom StargardtGeorg Juckel
Dec 4, 2012·International Journal of Environmental Research and Public Health·Elbert A MbukwaBhekie B Mamba